Plain-English fact sheet
Liraglutide
Also known as Victoza, Saxenda
Liraglutide is a GLP-1 receptor agonist with strong human evidence for the uses described in its FDA-approved product labels.
Quick answer
Liraglutide is FDA approved in products for type 2 diabetes and chronic weight management. Approval and age criteria depend on the exact product label.
By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.
What is Liraglutide?
Liraglutide is a manufactured GLP-1 analog. It acts on a receptor involved in blood-sugar regulation, appetite, and digestion.
Victoza and Saxenda contain liraglutide but have different labeled uses and should not be treated as a single generic claim.
Why are people interested in it?
Liraglutide has a longer clinical history than several other incretin medicines.
Readers often compare its evidence, schedule, outcomes, and risks with semaglutide and tirzepatide.
Current regulatory status
FDA-approved liraglutide products have indications for type 2 diabetes or chronic weight management in defined populations. Check current labeling for age and eligibility details.
What is it approved for?
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified adults and adolescents
- Reducing specified cardiovascular risks under the applicable label
FDA approval path
FDA approved for labeled products
FDA labels cover liraglutide products for specific diabetes and chronic-weight-management uses. The exact indication, age range, and risk language depend on the product.
Step 7 of 7
- DiscoveryBasic research
- PreclinicalLab and animal work
- Phase 1Initial human testing
- Phase 2Condition-focused trials
- Phase 3Confirmatory trials
- FDA reviewApplication review
- ApprovedLabel-specific use
Timeline source basis
What is it being studied for?
Investigational areas
- Other metabolic outcomes outside current labels
Evidence snapshot
Large clinical programs support approved uses, including cardiovascular outcomes evidence in a labeled diabetes population.
Potential benefits being researched
- Controlled trials support benefits for blood-sugar control and chronic weight management in labeled populations.
- The amount and type of benefit differ by population, endpoint, and product indication.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Gastrointestinal effects such as nausea, diarrhea, constipation, and vomiting are common.
- Labels include a boxed warning related to thyroid C-cell tumors in rodents and list important contraindications.
- Other concerns can include pancreatitis, gallbladder disease, kidney problems related to dehydration, and low blood sugar with certain other medicines.
What we still do not know
- How outcomes compare directly across related medicines and populations
- Whether research outside approved uses will produce meaningful clinical benefits
- Individual benefit-risk tradeoffs that require a clinician's review
Plain-English takeaway
Liraglutide is an established prescription medicine, but its evidence should be discussed by product, labeled use, population, and individual risks—not by class reputation alone.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1fdaFDA prescribing information: Victoza
Official prescribing information for a liraglutide type 2 diabetes product.
- 2
- 3clinical trialsClinicalTrials.gov: LEADER cardiovascular outcomes trial
Registry record for the liraglutide cardiovascular outcomes trial.
- 4pubmedLEADER liraglutide cardiovascular outcomes trial
Peer-reviewed report of a large liraglutide cardiovascular outcomes trial.